Speaker: Date: Topic
Vasileios C. Kyttaris, MD
Oct. 8, 2014
New Treatments for Rheumatic Diseases
Responsibility for Content
The WebEx video, PowerPoint presentation, take-away points, and article links were sent by the Medical Library and the CME Committee.
Diane E. Young, Information Specialist
Take-Away Points of the Presentation
1. Most rheumatoid arthritis patients are now on methotrexate.
2. Standard treatment for RA is to start methotrexate immediately, and if there is no response after 6 months, to try the TNF-a inhibitors.
3. Patients treated with TNF-α inhibitors are at higher risk for infections with reactivation of tuberculosis being a major concern. It is unclear whether these agents increase the risk of malignancies. Lipids are a concern with tocilizumab, not TNF-α inhibitors.
5. Belimumab is the first drug in the past 50 years to be approved for SLE.
6. We presently do not have any biomarkers to predict therapeutic response.
7. Cost is a huge concern with the newer drugs.